Concurrent chemotherapy and radiotherapy in patients with brain tumors

Michael J. Glantz, Lyndon Kim, Hak Choy, Wallace Akerley

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Because treatment for most brain tumors remains inadequate, there has been a sustained interest in using concurrent chemotherapy and radiotherapy to improve local control, prolong overall survival, and reduce treatment-related toxicity. Unfortunately, many currently available radiosensitizers are either ineffective against brain tumors or have a reduced ability to cross the blood-brain barrier when administered systemically. Many agents also have overlapping toxicities with cranial irradiation or enhance the toxicity of radiation in a way that potentially compromises care. Finally, the addition of chemotherapy to cranial irradiation complicates the assessment of tumor response. Despite these barriers, trials with a number of promising agents are currently under way. These trials have already provided crucial insights into the pharmacokinetics, clinical pharmacology, and practical management of brain tumor patients with concurrent chemotherapy and radiotherapy. These findings should rapidly lead to the safer and more effective use of combined-modality therapy in patients with central nervous system cancer.

Original languageEnglish (US)
Pages (from-to)78-82
Number of pages5
JournalOncology
Volume13
Issue number10 SUPPL. 5
StatePublished - 1999

Fingerprint

Brain Neoplasms
Cranial Irradiation
Radiotherapy
Drug Therapy
Combined Modality Therapy
Clinical Pharmacology
Blood-Brain Barrier
Neoplasms
Central Nervous System
Pharmacokinetics
Radiation
Survival
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Glantz, M. J., Kim, L., Choy, H., & Akerley, W. (1999). Concurrent chemotherapy and radiotherapy in patients with brain tumors. Oncology, 13(10 SUPPL. 5), 78-82.

Concurrent chemotherapy and radiotherapy in patients with brain tumors. / Glantz, Michael J.; Kim, Lyndon; Choy, Hak; Akerley, Wallace.

In: Oncology, Vol. 13, No. 10 SUPPL. 5, 1999, p. 78-82.

Research output: Contribution to journalArticle

Glantz, MJ, Kim, L, Choy, H & Akerley, W 1999, 'Concurrent chemotherapy and radiotherapy in patients with brain tumors', Oncology, vol. 13, no. 10 SUPPL. 5, pp. 78-82.
Glantz MJ, Kim L, Choy H, Akerley W. Concurrent chemotherapy and radiotherapy in patients with brain tumors. Oncology. 1999;13(10 SUPPL. 5):78-82.
Glantz, Michael J. ; Kim, Lyndon ; Choy, Hak ; Akerley, Wallace. / Concurrent chemotherapy and radiotherapy in patients with brain tumors. In: Oncology. 1999 ; Vol. 13, No. 10 SUPPL. 5. pp. 78-82.
@article{4ea0a63aa4e148569b1bdfb56fd605db,
title = "Concurrent chemotherapy and radiotherapy in patients with brain tumors",
abstract = "Because treatment for most brain tumors remains inadequate, there has been a sustained interest in using concurrent chemotherapy and radiotherapy to improve local control, prolong overall survival, and reduce treatment-related toxicity. Unfortunately, many currently available radiosensitizers are either ineffective against brain tumors or have a reduced ability to cross the blood-brain barrier when administered systemically. Many agents also have overlapping toxicities with cranial irradiation or enhance the toxicity of radiation in a way that potentially compromises care. Finally, the addition of chemotherapy to cranial irradiation complicates the assessment of tumor response. Despite these barriers, trials with a number of promising agents are currently under way. These trials have already provided crucial insights into the pharmacokinetics, clinical pharmacology, and practical management of brain tumor patients with concurrent chemotherapy and radiotherapy. These findings should rapidly lead to the safer and more effective use of combined-modality therapy in patients with central nervous system cancer.",
author = "Glantz, {Michael J.} and Lyndon Kim and Hak Choy and Wallace Akerley",
year = "1999",
language = "English (US)",
volume = "13",
pages = "78--82",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "10 SUPPL. 5",

}

TY - JOUR

T1 - Concurrent chemotherapy and radiotherapy in patients with brain tumors

AU - Glantz, Michael J.

AU - Kim, Lyndon

AU - Choy, Hak

AU - Akerley, Wallace

PY - 1999

Y1 - 1999

N2 - Because treatment for most brain tumors remains inadequate, there has been a sustained interest in using concurrent chemotherapy and radiotherapy to improve local control, prolong overall survival, and reduce treatment-related toxicity. Unfortunately, many currently available radiosensitizers are either ineffective against brain tumors or have a reduced ability to cross the blood-brain barrier when administered systemically. Many agents also have overlapping toxicities with cranial irradiation or enhance the toxicity of radiation in a way that potentially compromises care. Finally, the addition of chemotherapy to cranial irradiation complicates the assessment of tumor response. Despite these barriers, trials with a number of promising agents are currently under way. These trials have already provided crucial insights into the pharmacokinetics, clinical pharmacology, and practical management of brain tumor patients with concurrent chemotherapy and radiotherapy. These findings should rapidly lead to the safer and more effective use of combined-modality therapy in patients with central nervous system cancer.

AB - Because treatment for most brain tumors remains inadequate, there has been a sustained interest in using concurrent chemotherapy and radiotherapy to improve local control, prolong overall survival, and reduce treatment-related toxicity. Unfortunately, many currently available radiosensitizers are either ineffective against brain tumors or have a reduced ability to cross the blood-brain barrier when administered systemically. Many agents also have overlapping toxicities with cranial irradiation or enhance the toxicity of radiation in a way that potentially compromises care. Finally, the addition of chemotherapy to cranial irradiation complicates the assessment of tumor response. Despite these barriers, trials with a number of promising agents are currently under way. These trials have already provided crucial insights into the pharmacokinetics, clinical pharmacology, and practical management of brain tumor patients with concurrent chemotherapy and radiotherapy. These findings should rapidly lead to the safer and more effective use of combined-modality therapy in patients with central nervous system cancer.

UR - http://www.scopus.com/inward/record.url?scp=0033212155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033212155&partnerID=8YFLogxK

M3 - Article

C2 - 10550830

AN - SCOPUS:0033212155

VL - 13

SP - 78

EP - 82

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 10 SUPPL. 5

ER -